Mouse IFN-gamma Antibody

IFN‑ gamma Inhibition of EMCV-induced Cytopathy and Neutralization by Mouse IFN‑ gamma Antibody.

Recombinant Mouse IFN-gamma (Catalog # 485-MI) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line). Inhibition of EMCV activity elicited by Recombinant Mouse IFN-gamma (2.5 ng/mL) is neutralized (green line) by increasing concentrations of Hamster Anti-Mouse IFN-gamma Monoclonal Antibody (Catalog # MAB4851). The ND₅₀ is typically 4-20 ng/mL.

IFN‑ gamma in Mouse Splenocytes.

IFN‑ gamma was detected in immersion fixed mouse splenocytes stimulated with calcium ionomycin and PMA (left panel) or unstimulated (right panel) using Hamster Anti-Mouse IFN‑ gamma Monoclonal Antibody (Catalog # MAB4851) at 15 µg/mL for 3 hours at room temperature. Cells were stained using an anti-hamster IgG secondary antibody (red) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Non-adherent Cells.

Detection of IFN-gamma by Flow Cytometry

Dependency on FOXP3 in IFN gamma-mediated PD-L1 expression. A, Expression of FOXP3 and PD-L1 in bladder cancer HT1376, T24, and SW780 cell lines without and with 100 ng/mL IFN gamma stimulation by flow cytometry. The mean with SD of at least three independent experiments, P values indicated. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. B, Expression of FOXP3 and PD-L1 in HT1376 CT and HT1376 FOXP3 KO bladder cancer cell lines without and with IFN gamma stimulation by qPCR. The mean of triplicates and representative of three independent experiments, P values indicated. C, Expression of FOXP3 and PD-L1 in HT1376 CT and HT1376 FOXP3 KO lines without and with IFN gamma stimulation by Western blotting. Sizes in kD as indicated. Sizes of FOXP3 delta3 and FOXP3 depicted by overexpression in 293T cells. Full Western blots shown in Supplementary Fig. S1. D, Flow cytometry of FOXP3 and PD-L1 expression in HT1376 CT and HT1376 FOXP3 KO lines without and with IFN gamma stimulation. Representative of four independent experiments. E, Expression of FOXP3 and PD-L1 in rescue of a clonal HT1376 FOXP3 KO line by FOXP3 delta3 and FOXP3 overexpression. Representative of three independent experiments. F, Expression of FOXP3 and PD-L1 in HT1376 FOXP3 KO lines with reconstitution of FOXP3 delta3 and FOXP3 by Western blotting. Sizes in kD as indicated. Full Western blots shown in Supplementary Fig. S1. G, Flow cytometry of PD-L1 in HT1376 CT and HT1376 FOXP3 KO lines stimulated by IFN gamma without and with the presence of JAK1/2 inhibitor ruxolitinib (20 μmol/L), P values indicated. H, Expression of phosphorylated STAT1 (P-STAT1) in HT1376 CT and HT1376 FOXP3 KO lines stimulated by IFN gamma without and with the presence of JAK1/2 inhibitor ruxolitinib by Western blot. Full Western blots shown in Supplementary Fig. S1. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/39099201), licensed under a CC-BY license. Not internally tested by R&D Systems.